---
title: "Edwards Lifesciences CVP Daniel J. Lippis disposes of 619 common shares worth $56,762.3"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292358390.md"
description: "Edwards Lifesciences CVP Daniel J. Lippis sold 619 common shares worth $56,762.3 on July 10 at $91.7 per share. He simultaneously exercised employee stock options for the same number of shares at $72.68. Following these transactions, his direct holdings stand at 40,033 shares, with 4,952 remaining employee stock options."
datetime: "2026-07-10T21:05:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292358390.md)
  - [en](https://longbridge.com/en/news/292358390.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292358390.md)
---

# Edwards Lifesciences CVP Daniel J. Lippis disposes of 619 common shares worth $56,762.3

-   Edwards Lifesciences CVP, TAVR Daniel J. Lippis sold 619 shares on July 10 at USD 91.7. \* He also exercised employee stock options for 619 shares at USD 72.68 on the same day. \* Directly held common shares stood at 40,033 following the transactions. \* Employee stock options held totaled 4,952 following the exercise. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001225208-26-006576), on July 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [EW.US](https://longbridge.com/en/quote/EW.US.md)

## Related News & Research

- [Edwards Lifesciences Holding lifts Carvolix stake to 11.65% of capital, 9.07% voting rights](https://longbridge.com/en/news/293729797.md)
- [Edwards Earnings Add Fuel To Bullish MedTech Thesis, Analyst Says](https://longbridge.com/en/news/293778081.md)
- [Analyst Maintains Hold on Edwards with Neutral Risk-Reward and Reiterated $85 Price Target Amid Pending TAVR Catalysts](https://longbridge.com/en/news/293780167.md)
- [Edwards Lifesciences (NYSE:EW) Issues Earnings Results, Beats Expectations By $0.04 EPS](https://longbridge.com/en/news/293667107.md)
- [EW: Q2 sales up 12.5% year-over-year; guidance raised on strong TAVR and TMTT growth](https://longbridge.com/en/news/293676466.md)